claudin18.2治疗胃食管癌的进展。

IF 50 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Nature Medicine Pub Date : 2025-08-19 DOI:10.1038/s41591-025-03898-y

Samuel J. Klempner, Raghav Sundar

引用次数: 0

摘要

两项评估抗体-药物偶联物的一期试验确定了治疗晚期胃食管癌的潜在策略，并突出了claudin18.2靶向药物在实体肿瘤中的快速发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Evolution of claudin18.2 therapies in gastroesophageal cancers

查看原文本刊更多论文

Evolution of claudin18.2 therapies in gastroesophageal cancers

A pair of phase 1 trials evaluating antibody–drug conjugates identify potential strategies to treat advanced gastroesophageal cancers and highlight the rapid expansion of claudin18.2-targeting drug development in solid tumors.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Medicine 医学-生化与分子生物学

CiteScore

100.90

自引率

0.70%

发文量

525

审稿时长

1 months

期刊介绍： Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors. Nature Medicine consider all types of clinical research, including: -Case-reports and small case series -Clinical trials, whether phase 1, 2, 3 or 4 -Observational studies -Meta-analyses -Biomarker studies -Public and global health studies Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.